Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 17.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,581 shares of the company’s stock after selling 324 shares during the period. Sentry Investment Management LLC’s holdings in Moderna were worth $188,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MRNA. Vanguard Group Inc. boosted its position in shares of Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after acquiring an additional 5,129,800 shares during the last quarter. Wellington Management Group LLP raised its stake in Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares during the period. Capital World Investors boosted its holdings in Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Norges Bank purchased a new stake in shares of Moderna in the 4th quarter valued at approximately $347,565,000. Finally, Mawer Investment Management Ltd. increased its holdings in shares of Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after buying an additional 120,621 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $157.00 price objective (down from $214.00) on shares of Moderna in a report on Friday, August 2nd. Oppenheimer increased their price target on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Evercore ISI restated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. Finally, Royal Bank of Canada cut shares of Moderna from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $125.00 to $90.00 in a research report on Monday, August 5th. Ten equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $123.79.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the transaction, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 108,158 shares of company stock worth $13,239,712. Company insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $79.51 on Thursday. The company has a market cap of $30.56 billion, a price-to-earnings ratio of -5.07 and a beta of 1.68. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a fifty day simple moving average of $96.99 and a two-hundred day simple moving average of $112.15.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.62) EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.